{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:34:13Z","timestamp":1787668453071,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1456822","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:10:33Z","timestamp":1731906633000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiude","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Nils","year":"2015","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurology(R) Neuroimmunol Neuroinflammation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"QJM"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11910-016-0668-z","article-title":"Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis","volume":"16","author":"Hurst","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06842.x","article-title":"The role of B cell-activating factor in autoimmune myasthenia gravis","volume":"1274","author":"Lisak","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e94263, 94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e19416","DOI":"10.7759\/cureus.19416","article-title":"Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in anti-muSK positive and anti-AChR positive myasthenia gravis","volume":"13","author":"Bastakoti","year":"2021","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/CND.0000000000000374","article-title":"A case of muSK myasthenia gravis presenting with persistent respiratory insufficiency","volume":"23","author":"Tsai","year":"2021","journal-title":"J Clin Neuromuscular Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.12.004","article-title":"A very late onset AChR and MuSK double positive myasthenia gravis: a case description and literature review","volume":"33","author":"Pugliese","year":"2023","journal-title":"Neuromuscular Disorders: NMD"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.03.012","article-title":"AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review","volume":"30","author":"Lu","year":"2020","journal-title":"Neuromuscular Disorders: NMD"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.07.011","article-title":"Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent","volume":"486","author":"Bokoliya","year":"2018","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9466-17","article-title":"Anti-muSK antibody-positive myasthenia gravis successfully treated with outpatient periodic weekly blood purification therapy","volume":"57","author":"Deguchi","year":"2018","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4957-20","article-title":"Anti-muSK positive myasthenia gravis with anti-lrp4 and anti-titin antibodies","volume":"60","author":"Yamashita","year":"2021","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2576117X.2019.1578164","article-title":"Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (Anti-muSK-MG) in a child successfully treated with rituximab","volume":"69","author":"Weger","year":"2019","journal-title":"J Binocular Vision Ocular Motility"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26691","article-title":"Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravis","volume":"60","author":"Suh","year":"2019","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.04.011","article-title":"Two sisters with anti-MuSK-positive myasthenia gravis","volume":"182","author":"Kurt","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JND-190411","article-title":"Dysautonomia as the presenting symptom in anti-muscle-specific kinase antibody myasthenia gravis","volume":"7","author":"Bekooij","year":"2020","journal-title":"J Neuromuscular Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000410","article-title":"Double seropositive myasthenia gravis successfully treated with rituximab","volume":"24","author":"Sundaram","year":"2022","journal-title":"J Clin Neuromuscular Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1456822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:10:36Z","timestamp":1731906636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1456822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2024.1456822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1456822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"article-number":"1456822"}}